

## CORRECTION

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

Robert J. Moots, Ricardo M. Xavier, Chi Chiu Mok, Mahboob U. Rahman, Wen-Chan Tsai, Mustafa H. Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos

The images for Figs 4, 5, and 6 are incorrectly switched. The image that appears as Fig 4 should be Fig 5, the image that appears as Fig 5 should be Fig 6, and the image that appears as Fig 6 should be Fig 4. The figure captions appear in the correct order.

## Reference

 Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai W-C, Al-Maini MH, et al. (2017) The impact of antidrug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE 12(4): e0175207. doi:10.1371/journal.pone.0175207 PMID: 28448562



## **6** OPEN ACCESS

Citation: Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai W-C, Al-Maini MH, et al. (2017)
Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE 12(6): e0179308. https://doi.org/10.1371/journal.pone.0179308

Published: June 5, 2017

Copyright: © 2017 Moots et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.